Trial Profile
A Phase 2 Study of INCMGA00012 in Participants With Metastatic Merkel Cell Carcinoma (POD1UM-201)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 11 Dec 2023
Price :
$35
*
At a glance
- Drugs Retifanlimab (Primary)
- Indications Merkel cell carcinoma
- Focus Registrational; Therapeutic Use
- Acronyms POD1UM-201
- Sponsors Incyte Corporation
- 24 Oct 2023 Updated results from the full cohort of 101 pts presented at the 48th European Society for Medical Oncology Congress
- 16 Oct 2023 According to Incyte media release, updated results from this study will be presented t the upcoming European Society for Medical Oncology (ESMO) Congress 2023, held October 20-24 in Madrid.
- 04 Oct 2023 This trial has been completed in Spain.